Sorafenib is a multikinase inhibitor capable of facilitating apoptosis, mitigating angiogenesis
and suppressing tumor cell proliferation. In late-stage hepatocellular carcinoma (HCC) …

In most cases, sorafenib-resistant HCC cells exhibit significant mesenchymal phenotype and
stemness features. In this context, tumor cells might undergo cell fate transition in response …

Sorafenib is the first-line chemotherapeutic therapy for advanced hepatocellular carcinoma
(HCC). However, sorafenib resistance significantly limits its therapeutic efficacy, and the …

Background and aims Accumulating evidence suggests that the primary and acquired
resistance of hepatocellular carcinoma (HCC) to sorafenib is mediated by multiple …

Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related deaths
worldwide. HCC initiation, progression, and therapy failure are all influenced by various …

Hepatocellular carcinoma (HCC) is the fifth most common malignancy worldwide and the
second most lethal human cancer. A portion of patients with advanced HCC can significantly …

The treatment for hepatocellular carcinoma (HCC) is promising in recent years, but still
facing critical challenges. The first targeted therapy, sorafenib, prolonged the overall survival …

Hepatocellular carcinoma (HCC) continues to be a leading cause of cancer related death in
the world. Conventional chemotherapeutic agents such as cisplatin (CDDP) have an …

Abstract Rationale: PIWI-interacting RNAs (piRNAs), a class of newly discovered small RNA
molecules that function by binding to the Argonaute protein family (ie, the PIWIL protein …

Hepatocellular carcinoma (HCC) is one of the most common cancers, leading to the second
cancer-related death in the global. Although the treatment of HCC has greatly improved over …